NTRA

Natera
D

NTRA

138.884
USD
-2.30
(-1.63%)
مغلق
حجم التداول
52,955
الربح لكل سهم
-2
العائد الربحي
-
P/E
-94
حجم السوق
18,964,135,217
أصول ذات صلة
G
GH
-1.035
(-2.28%)
44.450 USD
HOLX
HOLX
0.370
(0.56%)
66.500 USD
ILMN
ILMN
1.730
(1.61%)
109.330 USD
M
MYGN
-0.20500
(-4.40%)
4.45000 USD
PODD
PODD
3.62
(1.26%)
290.23 USD
Q
QGEN
0.540
(1.05%)
51.800 USD
TMO
TMO
3.25
(0.68%)
478.43 USD
VEEV
VEEV
-0.77
(-0.26%)
290.48 USD
المزيد
الأخبار المقالات

العنوان: Natera

القطاع: Healthcare
الصناعة: Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.